Dermatitis, Photocontact Clinical Trial
Official title:
A Prospective, Open, Multi-Centre Photopatch Test Study of Patients Suspected of Photoallergy to Organic Sunscreens and Topical Nonsteroidal Anti-inflammatory Drugs Used Within Europe.
It is known that people can develop an allergic skin reaction to a substance which is placed
on the skin and then subjected to sunlight. This process is called Photocontact allergic
dermatitis. It is known that people can develop Photocontact allergic dermatitis to
sunscreen chemicals (filters) and also cream forms of pain-killing drugs called nonsteroidal
anti-inflammatory drugs (NSAIDs).
The purpose of this study is to determine the frequency of Photocontact allergic dermatitis
to 19 sunscreen filters and 5 topical NSAIDs in 1,000 European patients who present to a
dermatologist with a sun-exposed site dermatitis.
Each participant will have the 24 test agents plus one control of petrolatum applied to the
skin of the back for 24 or 48 hours. After removal of the substances, the area of skin will
be exposed to a precise amount of ultraviolet-A light. The area is then assessed 24, 48 and
72 hours later to see if a photocontact allergic reaction has occured. This method is known
as photopatch testing.
The study will run for one year, during which time it is planned to recruit 1,000 patients.
Specific Intervention Names:
- Butyl-methoxy-dibenzoylmethane
- Homosalate
- Methylbenzylidene camphor
- Benzophenone-3
- Octyl methoxycinnamate
- Phenylbenzimidazol sulfonic acid
- Benzophenone 4
- Drometrizole trisiloxane
- Octocrylene
- Octyl salicylate
- Octyl triazone
- Isoamyl-p-methoxycinnamate
- Terephtalidene dicamphor sulphonic acid (Mexoryl SX)
- Tinosorb S
- Tinosorb M
- Univul A+
- Neoheliopan AP
- Uvasorb HEB
- Parsol SLX
- Ketoprofen 1%
- Etofenamate 2%
- Piroxicam 1%
- Diclofenac 5%
- Ibuprofen 5 %
;
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic